IDEAS home Printed from https://ideas.repec.org/a/spr/pharmo/v8y2024i6d10.1007_s41669-024-00521-7.html
   My bibliography  Save this article

The Economic Impact of Introducing RefluxStop for Refractory Gastroesophageal Reflux Disease on the Italian Healthcare System

Author

Listed:
  • Sam Harper

    (York Health Economics Consortium)

  • Muralikrishnan Kartha

    (Implantica)

  • Stuart Mealing

    (York Health Economics Consortium)

  • Maurizio Pavanello

    (Ospedale di Conegliano)

  • Luigi Bonavina

    (University of Milan Medical School
    University of Milan Medical School)

Abstract

Introduction Gastroesophageal reflux disease (GERD) is a common ailment associated with troublesome symptoms. The standard of care in Italy involves initial treatment with proton pump inhibitor (PPI)-based medical management or laparoscopic Nissen fundoplication (LNF) for patients unwilling to continue or intolerant of long-term PPI therapy. RefluxStop is a novel medical device, intended for laparoscopic implantation, that has recently proven to be an efficacious and cost-effective treatment option for patients with GERD. This analysis aims to describe the short-term budget impact of introducing RefluxStop as a GERD treatment option within the Italian National Health Service (SSN). Methods A model adherent to international best practice recommendations was developed to estimate the budget impact of introducing RefluxStop over a 5-year time horizon. Two scenarios were considered: one without RefluxStop (i.e., comprising PPI therapy, LNF, and magnetic sphincter augmentation using the LINX system); and one with RefluxStop (i.e., addition of RefluxStop to the three treatment options previously mentioned). Clinical benefits and costs associated with each intervention were included in the analysis. Results Over 5 years, the introduction of RefluxStop resulted in avoidance of 95 surgical failures, 11 reoperations, and 64 endoscopic esophageal dilations. Introduction of RefluxStop resulted in an almost neutral impact on the existing budget with a 0.316% increase in the annual Italian SSN spending on GERD treatment. Conclusion Introduction of RefluxStop as a GERD treatment option in Italy is likely to be associated with substantial clinical benefits and a marginal budget impact.

Suggested Citation

  • Sam Harper & Muralikrishnan Kartha & Stuart Mealing & Maurizio Pavanello & Luigi Bonavina, 2024. "The Economic Impact of Introducing RefluxStop for Refractory Gastroesophageal Reflux Disease on the Italian Healthcare System," PharmacoEconomics - Open, Springer, vol. 8(6), pages 935-943, November.
  • Handle: RePEc:spr:pharmo:v:8:y:2024:i:6:d:10.1007_s41669-024-00521-7
    DOI: 10.1007/s41669-024-00521-7
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s41669-024-00521-7
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1007/s41669-024-00521-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharmo:v:8:y:2024:i:6:d:10.1007_s41669-024-00521-7. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.